129 related articles for article (PubMed ID: 3908127)
1. Follow-up study of enzymuria and beta 2 microglobulinuria during cis-platinum treatment.
Tirelli AS; Colombo N; Cavanna G; Mangioni C; Assael BM
Eur J Clin Pharmacol; 1985; 29(3):313-8. PubMed ID: 3908127
[TBL] [Abstract][Full Text] [Related]
2. Assessment of renal function during high-dose cis-platinum therapy in patients with ovarian carcinoma.
Buamah PK; Howell A; Whitby H; Harpur ES; Gescher A
Cancer Chemother Pharmacol; 1982; 8(3):281-4. PubMed ID: 6127169
[TBL] [Abstract][Full Text] [Related]
3. Urinary excretion of beta 2-microglobulin and N-acetyl-beta-D-glucosaminidase in advanced neuroblastoma patients receiving cis-diamminedichloroplatinum(II).
Ikeda H; Nagashima K; Okumura H; Takahashi A; Matsuyama S; Nagamachi Y
Eur J Surg Oncol; 1988 Feb; 14(1):17-20. PubMed ID: 3278937
[TBL] [Abstract][Full Text] [Related]
4. Comparison of methods of evaluating nephrotoxicity of cis-platinum.
Jones BR; Bhalla RB; Mladek J; Kaleya RN; Gralla RJ; Alcock NW; Schwartz MK; Young CW; Reidenberg MM
Clin Pharmacol Ther; 1980 Apr; 27(4):557-62. PubMed ID: 6987030
[TBL] [Abstract][Full Text] [Related]
5. Long-term renal effect of cisplatin in man.
Brillet G; Deray G; Jacquiaud C; Mignot L; Bunker D; Meillet D; Raymond F; Jacobs C
Am J Nephrol; 1994; 14(2):81-4. PubMed ID: 8080010
[TBL] [Abstract][Full Text] [Related]
6. [Clinical investigation of cis-platinum nephrotoxicity in 244 cases of primary lung cancer].
Soejima A; Inoue T; Suzuki M; Waku M; Nakabayashi K; Kitamoto K; Nagasawa T
Nihon Jinzo Gakkai Shi; 1992 Jul; 34(7):801-6. PubMed ID: 1479719
[TBL] [Abstract][Full Text] [Related]
7. [Cisplatin nephrotoxicity: effects on fractional excretion of sodium and enzymuria].
Cirami C; Bianchi AM; Galigani P; Gadducci A; Colombi L; Facchini V; Palla R
Minerva Med; 1990; 81(1-2):79-86. PubMed ID: 1969127
[TBL] [Abstract][Full Text] [Related]
8. Studies of enzymuria and beta 2-microglobulinuria in patients receiving prophylactic cefotaxime in obstetric and gynaecological surgery.
Ishikawa M; Yamashita K; Shimizu T
Drugs; 1988; 35 Suppl 2():178-80. PubMed ID: 3293974
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of methods for evaluating the nephrotoxicity of cisplatin].
Suzumori K; Yasui Y; Suzumori K; Yagami Y; Seki T
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2251-6. PubMed ID: 3044273
[TBL] [Abstract][Full Text] [Related]
10. [The effect of bismuth subnitrate on cisplatin toxicity].
Chen JT; Kurokawa Y; Nakayama K; Saito K; Sakamoto K; Fukuda K; Hirai Y; Hamada T; Fujimoto I; Yamauchi K
Nihon Sanka Fujinka Gakkai Zasshi; 1987 May; 39(5):815-22. PubMed ID: 3298471
[TBL] [Abstract][Full Text] [Related]
11. [Studies of enzymuria and proteinuria: Report 2; Relationship between glomerular filtration rate and urinary enzymuria and proteinuria].
Yasumoto R; Tanaka S; Kawashima H; Kakinoki K; Iseki T; Umeda M; Tanabe S; Nishisaka N; Asakawa M
Hinyokika Kiyo; 1989 Jul; 35(7):1125-8. PubMed ID: 2478007
[TBL] [Abstract][Full Text] [Related]
12. [Studies on serum and urinary alpha 1-microglobulin levels as parameter of the renal function--renal function observed after CDDP administration].
Ujiie T; Maruta H; Ito N
Hinyokika Kiyo; 1988 May; 34(5):790-6. PubMed ID: 2459938
[TBL] [Abstract][Full Text] [Related]
13. Urinary endothelin-1-like immunoreactivity in young male patients with testicular cancer treated by cis-platinum: comparison with other urinary parameters.
Takeda M; Komeyama T; Tsutsui T; Mizusawa T; Go H; Hatano A; Tanikawa T
Clin Sci (Lond); 1994 Jun; 86(6):703-7. PubMed ID: 7520380
[TBL] [Abstract][Full Text] [Related]
14. [Renal tubular impairment in traumatized patients].
Yokota J; Sakamoto T; Uenishi M; Shibuya M; Hashimoto K; Yoshioka T; Sugimoto T
Nihon Geka Gakkai Zasshi; 1986 Nov; 87(11):1391-7. PubMed ID: 3537681
[TBL] [Abstract][Full Text] [Related]
15. Nephrotoxicity of cis-diamminedichloroplatinum with or without ifosfamide in cancer treatment.
Hacke M; Schmoll HJ; Alt JM; Baumann K; Stolte H
Clin Physiol Biochem; 1983; 1(1):17-26. PubMed ID: 6383688
[TBL] [Abstract][Full Text] [Related]
16. [Determination of urinary N-acetyl-beta-D-glucosaminidase (NAG) excretion as a parameter of nephrotoxicity due to cis-platin and the effect of fosfomycin (FOM) on its nephrotoxicity].
Matsuoka R; Inoue T; Miyamura K; Mizutani K; Koike S; Mori H; Kigawa T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Nov; 38(11):2037-44. PubMed ID: 3794453
[TBL] [Abstract][Full Text] [Related]
17. Comparison of renal function parameters in the assessment of cis-platin induced nephrotoxicity.
Verplanke AJ; Herber RF; de Wit R; Veenhof CH
Nephron; 1994; 66(3):267-72. PubMed ID: 7910667
[TBL] [Abstract][Full Text] [Related]
18. Administration of gallium nitrate by continuous infusion: lack of chronic nephrotoxicity confirmed by studies of enzymuria and beta 2-microglobulinuria.
Leyland-Jones B; Bhalla RB; Farag F; Williams L; Coonley CJ; Warrell RP
Cancer Treat Rep; 1983 Oct; 67(10):941-2. PubMed ID: 6354440
[TBL] [Abstract][Full Text] [Related]
19. Cumulative renal tubular damage associated with cisplatin nephrotoxicity.
Goren MP; Wright RK; Horowitz ME
Cancer Chemother Pharmacol; 1986; 18(1):69-73. PubMed ID: 2875808
[TBL] [Abstract][Full Text] [Related]
20. Enzymuria in carboplatin nephrotoxicity.
Damiani E; Cattaneo MT; Sessa C; Zucca E; Cavalli F; Bertolini A; Libretti A; Beretta R
Tumori; 1987 Oct; 73(5):487-91. PubMed ID: 3318051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
